587 related articles for article (PubMed ID: 26629307)
21. [Research advances in the pathogenesis of non-alcoholic fatty liver disease-associated liver cancer].
Huang W; Zhang XX
Zhonghua Gan Zang Bing Za Zhi; 2017 Feb; 25(2):157-160. PubMed ID: 28297806
[TBL] [Abstract][Full Text] [Related]
22. Lifestyle intervention for morbid obesity: effects on liver steatosis, inflammation, and fibrosis.
Hohenester S; Christiansen S; Nagel J; Wimmer R; Artmann R; Denk G; Bischoff M; Bischoff G; Rust C
Am J Physiol Gastrointest Liver Physiol; 2018 Sep; 315(3):G329-G338. PubMed ID: 29878845
[TBL] [Abstract][Full Text] [Related]
23. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009.
Younossi ZM; Otgonsuren M; Henry L; Venkatesan C; Mishra A; Erario M; Hunt S
Hepatology; 2015 Dec; 62(6):1723-30. PubMed ID: 26274335
[TBL] [Abstract][Full Text] [Related]
24. Ruptured hepatocellular carcinoma and non-alcoholic fatty liver disease, a potentially life-threatening complication in a population at increased risk.
Nuño-Guzmán CM; Marín-Contreras ME
Ann Hepatol; 2020; 19(1):3-4. PubMed ID: 31916949
[No Abstract] [Full Text] [Related]
25. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.
Perumpail BJ; Khan MA; Yoo ER; Cholankeril G; Kim D; Ahmed A
World J Gastroenterol; 2017 Dec; 23(47):8263-8276. PubMed ID: 29307986
[TBL] [Abstract][Full Text] [Related]
26. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people: do they lead to over-referral?
Blond E; Disse E; Cuerq C; Drai J; Valette PJ; Laville M; Thivolet C; Simon C; Caussy C
Diabetologia; 2017 Jul; 60(7):1218-1222. PubMed ID: 28352941
[TBL] [Abstract][Full Text] [Related]
27. The Natural Course of Non-Alcoholic Fatty Liver Disease.
Calzadilla Bertot L; Adams LA
Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27213358
[TBL] [Abstract][Full Text] [Related]
28. Non-alcoholic fatty liver disease and hepatocellular carcinoma in a 7-year-old obese boy: coincidence or comorbidity?
Nobili V; Alisi A; Grimaldi C; Liccardo D; Francalanci P; Monti L; Castellano A; de Ville de Goyet J
Pediatr Obes; 2014 Oct; 9(5):e99-e102. PubMed ID: 24302697
[TBL] [Abstract][Full Text] [Related]
29. [Non-alcoholic fatty liver disease; a full-bodied epidemic].
Tushuizen ME; Holleboom AG; Koot BGP; Blokzijl H; van Mil SWC; Koek GH
Ned Tijdschr Geneeskd; 2020 Feb; 164():. PubMed ID: 32267638
[TBL] [Abstract][Full Text] [Related]
30. Diabetic Retinopathy as a Risk Factor Associated with the Development of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.
Azuma S; Asahina Y; Kakinuma S; Azuma K; Miyoshi M; Inoue E; Tsunoda T; Sato A; Kaneko S; Nagata H; Kawai-Kitahata F; Murakawa M; Nitta S; Itsui Y; Tomita M; Nakagawa M; Watanabe M
Dig Dis; 2019; 37(3):247-254. PubMed ID: 30625487
[TBL] [Abstract][Full Text] [Related]
31. Transarterial bland versus chemoembolization for hepatocellular carcinoma: rethinking a gold standard.
Massarweh NN; Davila JA; El-Serag HB; Duan Z; Temple S; May S; Sada YH; Anaya DA
J Surg Res; 2016 Feb; 200(2):552-9. PubMed ID: 26507276
[TBL] [Abstract][Full Text] [Related]
32. Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH.
Salomao M; Yu WM; Brown RS; Emond JC; Lefkowitch JH
Am J Surg Pathol; 2010 Nov; 34(11):1630-6. PubMed ID: 20975341
[TBL] [Abstract][Full Text] [Related]
33. Nonalcoholic steatohepatitis.
Brunt EM
Semin Liver Dis; 2004 Feb; 24(1):3-20. PubMed ID: 15085483
[TBL] [Abstract][Full Text] [Related]
34. Liver Resection for Nonalcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma.
Koh YX; Tan HJ; Liew YX; Syn N; Teo JY; Lee SY; Goh BKP; Goh GBB; Chan CY
J Am Coll Surg; 2019 Nov; 229(5):467-478.e1. PubMed ID: 31398386
[TBL] [Abstract][Full Text] [Related]
35. A micro-RNA expression signature for human NAFLD progression.
Guo Y; Xiong Y; Sheng Q; Zhao S; Wattacheril J; Flynn CR
J Gastroenterol; 2016 Oct; 51(10):1022-30. PubMed ID: 26874844
[TBL] [Abstract][Full Text] [Related]
36. Nonalcoholic fatty liver disease - current status and future directions.
Demir M; Lang S; Steffen HM
J Dig Dis; 2015 Oct; 16(10):541-57. PubMed ID: 26406351
[TBL] [Abstract][Full Text] [Related]
37. Tuberculosis reactivation in hepatocellular carcinoma: association with transarterial chemoembolization.
Laake AM; Liappis AP; Guy E; Kerr G; Benator DA
Infect Dis (Lond); 2015 Apr; 47(4):267-70. PubMed ID: 25688446
[TBL] [Abstract][Full Text] [Related]
38. A comparison of chemoembolization with conventional chemotherapy and symptomatic treatment in cirrhotic patients with hepatocellular carcinoma.
Bayraktar Y; Balkanci F; Kayhan B; Uzunalimoglu B; Gokoz A; Ozisik Y; Gurakar A; Van Thiel DH; Firat D
Hepatogastroenterology; 1996; 43(9):681-7. PubMed ID: 8799415
[TBL] [Abstract][Full Text] [Related]
39. [Research on the natural history of non-alcoholic fatty liver disease should be taken seriously].
Zhao ZH; Liu XL; Fan JG
Zhonghua Gan Zang Bing Za Zhi; 2017 Feb; 25(2):81-84. PubMed ID: 28297791
[TBL] [Abstract][Full Text] [Related]
40. [Overview of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Management].
Kim SK; Kim KI; Kim SR
Yakugaku Zasshi; 2019; 139(9):1147-1153. PubMed ID: 31474630
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
